Streetbeat News

SIGA

SIGA Technologies, Inc.

https://www.siga.com

Industry

Drug Manufacturers - Specialty & Generic

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Open

6.18

Mkt cap

441M

Volume

416K

High

6.32

P/E Ratio

5.28

52-wk high

12.83

Low

5.94

Div yield

0.10

52-wk low

4.26

SIGA Technologies has entered an exclusive license agreement with Vanderbilt University to acquire a portfolio of preclinical fully human poxvirus monoclonal antibodies. This strategic move could enhance SIGA's product offerings in the field of antiviral treatments.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:31 am

SIGA Technologies has entered into an agreement to supply its antiviral drug TPOXX (Tecovirimat) to Morocco, marking its first commercial sale of the drug in Africa. This move is in response to Morocco's Ministry of Health's request to prepare for potential mpox outbreaks.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:33 am

The WHO has announced a $135M strategic plan to combat the mpox outbreak, focusing on vaccination and prevention efforts. Companies like Bavarian Nordic, Emergent Biosolutions, GeoVax Labs, and SIGA Technologies, which are involved in mpox vaccines and treatments, have seen stock volatility.

Portfolio Pulse from Chris Katje

August 26, 2024 | 7:58 pm

SIGA Technologies, Inc. (NASDAQ:SIGA) announced a $9 million contract with the U.S. Department of Defense for TPOXX, boosting its order book despite recent trial disappointments. Analysts expect improved investor sentiment due to this contract win.

Portfolio Pulse from Vandana Singh

August 23, 2024 | 6:29 pm

SIGA Technologies shares rise following a $9 million contract award from the U.S. Department of Defense for the procurement of TPOXX.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 8:02 pm

SIGA Technologies, Inc. has secured a $9 million contract with the U.S. Department of Defense for the procurement of TPOXX, marking the third such contract in three years. This deal includes both oral and intravenous forms of TPOXX and is part of ongoing collaboration with the DOD.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 8:01 pm

A new mpox variant, Clade I, is causing global concern, with increased screening in Europe and China. The variant is more severe and transmissible, prompting vaccine and drug developments. Bavarian Nordic and SIGA Technologies are key players in the vaccine and treatment landscape.

Portfolio Pulse from Michael Juliano

August 19, 2024 | 6:26 pm

SIGA Technologies Inc (NASDAQ:SIGA) experienced a significant price drop after releasing disappointing trial data for a Mpox treatment, followed by a brief surge. The stock is currently facing a 'bull trap,' indicating potential further declines.

Portfolio Pulse from Mark Putrino

August 16, 2024 | 6:17 pm

H&R Block reported better-than-expected Q4 earnings and issued strong FY25 guidance, leading to a 16.4% rise in its stock price. Other notable gainers include Emergent BioSolutions, AST SpaceMobile, Rocket Lab USA, Planet Labs, Jumia Technologies, Polestar Automotive, SIGA Technologies, Ambipar Emergency Response, Treace Medical Concepts, CI&T, QXO, Cellebrite DI, JD.com, and Alibaba Group.

Portfolio Pulse from Avi Kapoor

August 16, 2024 | 2:15 pm

The European Centre for Disease Prevention and Control (ECDC) has warned of likely Mpox cases in the EU/EEA originating from Africa. However, the risk of sustained transmission is low with quick diagnosis and control measures.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 11:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.